Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

NCT04913103 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Mantle-Cell

Interventions

DRUG: Polatuzumab vedotin
DRUG: Bendamustine Hydrochloride
DRUG: Rituximab

Sponsor

Czech Lymphoma Study Group